Sign in

    Chenin Lei Wang

    Research Analyst at CICC

    Chenin Lei Wang is an Executive Director and Analyst at China International Capital Corporation (CICC), specializing in healthcare and pharmaceutical sector research with a focus on covering major Chinese life sciences and biopharmaceutical companies such as WuXi AppTec, Jiangsu Hengrui Medicine, and CSPC Pharmaceutical Group. Renowned for her in-depth equity research and investment recommendations, she is recognized by industry platforms for high forecast accuracy and a robust success rate, frequently ranking among the top healthcare analysts in the APAC region and delivering above-benchmark returns. Wang began her professional journey in equities research after graduating from Fudan University, joining CICC in 2015 and advancing through roles of increasing responsibility. She holds all relevant securities licenses in China and is known for her contribution to award-winning research teams.

    Chenin Lei Wang's questions to Agora (API) leadership

    Chenin Lei Wang's questions to Agora (API) leadership • Q2 2025

    Question

    Chenin Lei Wang from CICC asked about the market reception for the newly launched advanced attention locking and interactive avatar features. She sought details on early adoption trends and client feedback on these innovations.

    Answer

    The CEO responded that these features were designed based on real-world applications and customer needs identified during early adoption. He elaborated that advanced attention locking is essential for noisy environments, citing the Fuzuzu AI companion toy as an example. He also described interactive avatars as a 'must-have' for creating lifelike, engaging interactions in use cases like education and customer service.

    Ask Fintool Equity Research AI